Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 and Cabazitaxel in mCRPC
NCT02035124Phase 2Withdrawn
- Sponsor
- SCRI Development Innovations
- Start
- Apr 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SCRI Development Innovations. Planned start Apr 2014; status: withdrawn.
02
Drugs
buparlisib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02035124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035124.